Early success in the inaugural transplant of a pig kidney into a human recipient has sparked optimism among researchers for broader clinical trials involving pig organs. These trials could pave the way for xenotransplantation, the utilization of animal organs in human patients, to become a viable medical option. The recipient of the pig kidney, 62-year-old Richard Slayman, who suffered from end-stage renal failure, is reportedly recovering well following his surgery on March 16th, as confirmed by his transplant surgeon. The kidney was sourced from a miniature pig carrying an impressive 69 genomic edits, aimed at minimizing organ rejection and mitigating the risk of viral transmission to the recipient. Luhan Yang, CEO of Qihan Biotech in Hangzhou, China, and a founder of eGenesis in Cambridge, Massachusetts, the biotech firm responsible for producing the genetically modified pigs, asserts that this case demonstrates the short-term safety and functionality of these organs as viable kidney replacements. Watch to know more
first published: Mar 27, 2024 03:07 pm
A collection of the most-viewed Moneycontrol videos.

Live: Can Nifty reach its all-time high levels this week? | Opening Bell

This Tenant says Andheri West is better than SOBO | The tenant

Nifty Clocks Second Week Of Gains But Still Awaits New Peak;Midcaps Snap 7-Week Run|Closing Bell

Will Nifty Bulls March Towards Fresh Peak Despite Dismal Global Cues? | Opening Bell Live
You are already a Moneycontrol Pro user.

